Navigation Links
Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Date:8/4/2008

EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.1 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies CEO to Retire on December 31, 2008
2. Neurobiological Technologies Reports Third Quarter Financial Results
3. Neurobiological Technologies Sets Date for Third Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Sets Date for Research and Development Day
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture ... the company’s board of directors. This addition continues to strengthen and diversify VIC’s ... Goforth, CEO and Chairman. “He is a highly accomplished business executive with a broad ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... that accelerate pharmaceutical and biotherapeutics development, announces the launch of a new NTA ... biosensor chip enables researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation ... the first phase of the Allotrope Framework for commercial use. , The Bio-IT ... to “not only elevate the critical role of information technology in modern biomedical ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Heavy-Duty ... orbital shaker models (both analog and digital) for laboratory applications. These shakers ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):